Delcath’s Chemotherapy Device Has Risks, FDA Staff Says

Delcath Systems Inc.’s experimental drug-and-device combination for chemotherapy carries life-threatening risks that may outweigh any benefit, U.S. Food and Drug Administration staff said. The shares fell the most in more than five years .

To continue reading this article you must be a Bloomberg Professional Service Subscriber.